Q1 EPS Estimate for Halozyme Therapeutics Lifted by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities research analysts at Zacks Research boosted their Q1 2025 EPS estimates for shares of Halozyme Therapeutics in a research note issued to investors on Tuesday, January 7th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.98 per share for the quarter, up from their prior estimate of $0.97. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.33 EPS, FY2025 earnings at $4.50 EPS, Q3 2026 earnings at $1.38 EPS and Q4 2026 earnings at $1.63 EPS.

A number of other brokerages have also issued reports on HALO. HC Wainwright upped their target price on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research note on Friday. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. JMP Securities upped their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Finally, Piper Sandler upped their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $61.44.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $52.80 on Thursday. The firm has a market cap of $6.72 billion, a PE ratio of 17.48, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24. The firm’s 50-day simple moving average is $50.23 and its 200-day simple moving average is $54.00. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics has a 1 year low of $33.15 and a 1 year high of $65.53.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 2.70% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its holdings in Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 350 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new stake in Halozyme Therapeutics in the 2nd quarter valued at $49,000. Toth Financial Advisory Corp bought a new position in shares of Halozyme Therapeutics during the 3rd quarter worth about $57,000. FSC Wealth Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 3rd quarter worth about $65,000. Finally, Park Place Capital Corp lifted its holdings in shares of Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 1,209 shares during the period. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.